HR+/HER2- - PCE Oncology 2022 Spring

Share

Program Content

Activities

  • HR+/HER2- Breast Cancer
    CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: Addressing Barriers to Their Optimal Use
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 22, 2022

    Expires: April 21, 2023

    View Activity
  • Considerations When Managing HR+/HER2- Breast Cancer With CDK4/6 Inhibitors
    Considerations When Managing HR+/HER2- Breast Cancer With CDK4/6 Inhibitors
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 31, 2022

    Expires: May 30, 2023

    View Activity
  • Nursing Considerations for CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
    Nursing Considerations for CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
    Podcast Episodes
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 30, 2022

    Expires: June 29, 2023

    View Activity
  • CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: Addressing Barriers to Their Optimal Use
    CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: Addressing Barriers to Their Optimal Use
    Patient Simulation
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 16, 2022

    Expires: September 15, 2023

    View Activity

Faculty

cover img faculity

Julia LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
UCLA Hematology Oncology
Los Angeles, California

cover img faculity

Julia LaBarbera, MSN, RN, AGACNP-BC

  • Nurse Practitioner
    Division of Hematology/Oncology
    Department of Medicine
    University of California, Los Angeles
    Santa Monica, California